Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 623 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs... October 16, 2025 Scientists Link a Single Type of Bacteria to Colorectal Cancer April 19, 2024 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 Immunotherapy approved for some people with oesophageal cancer on NHS in... October 20, 2021 Load more HOT NEWS Her Mother Died of Breast Cancer When She Was Five. 16... Different Microbiota–Host Relationships Relevant to Distinct Immune Checkpoint Blockade Regimens FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... Drug Combo JAKs Up Immunotherapy in Two Clinical Trials
